ATRIAL FIBRILLATION IN COMORBID PATIENTS DEPENDING ON THE TREATMENT REGIMEN

Aim. To study the clinical course of atrial fibrillation in patients with arterial hypertension and extracardiac comorbid pathology depending on the administered therapy.

Methods. 207 men aged 45–65 years with atrial fibrillation (paroxysmal and persistent) and arterial hypertension in combination with diabetes mellitus (n = 40), abdominal obesity (n = 64) and chronic obstructive pulmonary disease (n = 47) were recruited to a observational cohort study. 56 patients with atrial fibrillation and arterial hypertension but without any extracardiac diseases were included in the comparison group. Clinical and anthropometric parameters were assessed in all patients. Adherence to therapy was estimated with the Morisky-Green test. All patients underwent ECG; electrocardiographic holter monitoring, 24-hour blood pressure monitoring with the Daily Monitoring Systems SCHILLER (Schiller, Switzerland), 2D and M-mode echocardiography using a Vivid 7 device (General Electric, USA). The statistical analysis was performed in the Rstudio software (version 0.99.879, RStudio, Inc., MA, USA).

Results. 66% of patients with atrial fibrillation and arterial hypertension had concomitant extracardiac comorbid pathology, of them 20% of had diabetes mellitus, 22% with chronic obstructive pulmonary disease, and 24% with abdominal obesity. The clinical groups were comparable in electro impulse and drug therapy. Patients who received medical treatment were frequently admitted to hospitals for atrial fibrillation recurrence (p<0.001), compared with those who underwent electro impulse therapy. Adherence to antiarrhythmic therapy was low in the entire cohort of patients. There were no significant differences found between the clinical groups.

Conclusion. Early diagnosis of the factors contributing to the progression of AF, the prescription of additional therapy for the secondary prevention of arrhythmia and the choice of its optimal treatment strategy may slow the progression of arrhythmia and the development of CHF, which will improve not only the clinical status of patients, but also their prognosis.

1. Chasоv E.I., Gоlycyna S.P. Guide tò Cardiac Arrhythmias. Moscow: Geоtar-Media, 2010 р232-99 (in Russian)

2. Diagnosis and treatment of atrial fibrillation. Russian Journal of Cardiology. 2017;7(147):7–86 (in Russian) doi: 10.15829/1560-4071-2017-7-7-86

3. Proietti M., Laroche C., Nieuwlaat R., Crijns H-J.G.M., Maggioni A.P.5 Lane D.A., Boriani G., Lip G.Y.H.; EORP-AF General Pilot Registry; Euro Heart Survey on AF Investigators. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018 doi:10.1016/j.ejim.2018.05.016.

4. Apostolakis S., Sullivan R.M., Olshansky B., Lip G.Y. Left ventricular geometry and outcomes in patients with atrial fibrillation: the AFFIRM Trial. Int J Cardiol. 2014;170(3):3038. doi:10.1016/j.ijcard.2013.11.002.

5. Barbarash O.L., Usoltseva E.N. Heart failure treatment under control of natriuretic peptides concentration. Complex Issues of Cardiovascular Diseases. 2014;(1):67-74. (in Russian) doi:10.17802/2306-1278-2014-1-67-74

6. Weijs B., Pisters R., Nieuwlaat R., Breithardt G., Le Heuzey J.Y., Vardas P.E., Limantoro I., Schotten U., Lip G.Y., Crijns H.J. Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort Europace. 2012;14(2):184-90. doi:10.1093/europace/eur379.

7. Ogawa H., An Y., Ikeda S., Aono Y., Doi K., Ishii M., Iguchi M., Masunaga N., Esato M., Tsuji H., Wada H., Hasegawa K., Abe M., Lip G.Y.H., Akao M.; Fushimi AF Registry Investigators. Progression From Paroxysmal to Sustained Atrial Fibrillation Is Associated With Increased Adverse Events. Stroke. October 2018;49 (10): 2301-2308. doi: 10.1161/STROKEAHA.118.021396.

8. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.

9. Verma A., Champagne J., Sapp J., Essebag V., Novak P., Skanes A., Morillo C.A., Khaykin Y., Birnie D.. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern. Med. 2013;173(2):149–156. doi: 10.1001/ jamainternmed.2013.1561М

10. Malysh E.Yu., Drobysheva Ye.S., Chernov A.V. Chronic obstructive lung disease and damage to the cardiovascular system. Young Scientist. 2014;5:145-148. (in Russian)

11. Katritsis, D. G., Boriani, G., Cosio, F. G., Hindricks, G., Jais, P., Josephson, M. E., Keegan R., Kim Y.H., Knight B.P., Kuck K.H., Lane D.A., Lip G.Y.H., Malmborg H., Oral H., Pappone C., Themistoclakis S., Wood K.A., BlomströmLundqvist C. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE). European Heart Journal, 39(16), 1442-1445. doi:10.1093/eurheartj/ehw455

12. Pokushalov E, Romanov A, Corbucci G., Artyomenko S., Turov A., Shirokova N., Karaskov A. Use of an implantable monitor to detect arrhythmia recurrences and select patients for early repeat catheter ablation for atrial fibrillation: a pilot study. Circ Arrhythm Electrophysiol. 2011;4(6):823-31. doi:10.1161/ CIRCEP.111.964809.

13. Castiglioni P., Lazzeroni D., Coruzzi P., Faini A. Corrigendum to: Multifractal-Multiscale Analysis of Cardiovascular Signals: A DFA-Based Characterization of Blood Pressure and Heart-Rate Complexity by Gender. Complexity . 2018; 2018: 4801924. doi:10.1155/2018/5426860

14. Schnabel R.B., Yin X., Gona P., Larson M.G., Beiser A.S., McManus D.D., Newton-Cheh C., Lubitz S.A, Magnani J.W., Ellinor P.T., Seshadri S., Wolf P.A., Vasan R.S., Benjamin E.J., Levy D. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. Jul 11; 386(9989):154-62. doi:10.1016%2FS0140-6736(14)61774-8.

15. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace, 2017;9(6):335-379. doi: 10.1093/europace/eum120

16. Le Heuzey, J. Y., De Ferrari, G. M., Radzik, D., Santini, M., Zhu, J., & Davy, J. M. (2010). A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The dionysos study. J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605. doi: 10.1111/j.15408167.2010.01764.x.